AbbVie Reports Positive Phase 3 Results for Epcoritamab Combination

The trial, which compared the novel bispecific antibody combination against the standard R-GemOx chemoimmunotherapy, met its primary endpoint for adult patients who had received at least one prior line of therapy. Researchers observed a 60% reduction in the risk of disease progression and death in U.S. study cohorts, with a 56% reduction reported in international participants. The safety data remained consistent with the established profiles of the individual agents.

"These results highlight the potential of epcoritamab as a meaningful treatment option after initial disease progression," said Daejin Abidoye, AbbVie’s vice president of oncology. The company plans to share the full data set at an upcoming medical meeting and engage with global regulatory authorities to discuss potential next steps for the therapy. The ongoing trial, initiated in August 2024, continues to evaluate the combination across a broad spectrum of large B-cell lymphoma subtypes.